Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Psoriasis 1Prostatic Neoplasms 1Precancerous Conditions 1Paget's Disease, Mammary 1Osteoarthritis 1Obesity 1Neoplasms 1Neoplasm, Residual 1Fatigue 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Cachexia 1Breast Carcinoma In Situ 1Barrett Esophagus 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Aggressive Periodontitis 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms × Docosahexaenoic Acids × Clear all
NCT02352779 2017-08-08

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors

University of Rochester

Phase NA Completed
108 enrolled 17 charts
Breast

Breast Neoplasms, Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡